PGHL5,435.00

Procter & Gamble Health Limited

· Pharma & Health
₹ CrorePeersSANOFICONRSANOFISENORESINNOVACAPMOREPENLABIOLCPFDCASTRAZENMcap ₹9,022 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY25
30/06/2024
FY26
30/06/2025
FY27
30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×0.740.750.74
Interest Burden (Pretax/EBIT) ×0.981.051.38
EBIT Margin %24.2025.0625.73
Asset Turnover ×1.450.430.46
Financial Leverage (Assets/Equity) ×1.48
ROE (5-step product) %37.36
ROE (reported, avg-equity basis) %37.3412.3017.86
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY27 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.